Solvay Settles Estratest False Marketing Suit For $16M
A federal judge has granted final approval to a $16.5 million class action settlement that will end a lawsuit accusing Solvay Pharmaceuticals Inc. of falsely marketing menopause-treating drugs as if they...To view the full article, register now.
Already a subscriber? Click here to view full article